A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 19 Oct 2017 Status changed from active, no longer recruiting to completed.
- 16 Oct 2017 Results published in a Sanofi Media Release.
- 16 Oct 2017 According to a Sanofi media release, data were presented at the World Congress of Gastroenterology (WCOG) 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History